ACTINIUM PHARMACEUTICALS INC

NYSE: ATNM (Actinium Pharmaceuticals, Inc.)

Kemas kini terakhir: 25 Dec, 2024, 6:02PM

1.22

-0.02 (-1.61%)

Penutupan Terdahulu 1.24
Buka 1.24
Jumlah Dagangan 141,941
Purata Dagangan (3B) 299,665
Modal Pasaran 38,059,000
Harga / Jualan (P/S) 517.80
Harga / Buku (P/B) 1.18
Julat 52 Minggu
1.10 (-9%) — 10.24 (739%)
Tarikh Pendapatan 14 Nov 2024
Margin Operasi (TTM) -57,665.44%
EPS Cair (TTM) -1.39
Jumlah Hutang/Ekuiti (D/E MRQ) 4.22%
Nisbah Semasa (MRQ) 8.95
Aliran Tunai Operasi (OCF TTM) -33.96 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -20.06 M
Pulangan Atas Aset (ROA TTM) -30.91%
Pulangan Atas Ekuiti (ROE TTM) -87.96%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Actinium Pharmaceuticals, Inc. - -

AISkor Stockmoo

0.0
Konsensus Penganalisis 0.0
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal -2.5
Osilator Teknikal 2.0
Purata 0.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ATNM 38 M - - 1.18
CYBN 190 M - - 1.21
PLX 130 M - - 4.81
ANRO 119 M - - 0.640
LCTX 110 M - - 1.86
ARMP 74 M - - 4.06

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 1.79%
% Dimiliki oleh Institusi 30.11%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

1.511.511.381.381.261.261.131.131.001.00Dec 27Dec 27Dec 30Dec 30Dec 31Dec 31Jan 2Jan 2Jan 3Jan 3Jan 6Jan 6Jan 7Jan 7Jan 8Jan 8

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0500.050-0.000-0.000-0.050-0.050-0.100-0.100-0.150-0.150MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda